Foghorn Therapeutics (FHTX) is scheduled to report Q1 earnings on May 13, 2026. Analysts estimate EPS of $-0.31 and quarterly revenue of $8.42M.

In the most recent quarter (Q4), Foghorn Therapeutics reported EPS of $-0.34, missing estimates of $-0.27 by 0.26%. Revenue came in at $9.25M, exceeding the estimate of $8.95M by 0.03%.

Over the last 4 quarters, Foghorn Therapeutics has averaged an EPS surprise of 0.19% and a revenue surprise of 0.08%.